Data thru May 13, 2026
HomeTrendsArticlesDrug MarketsTherapeutic ClassesManufacturersPricingContact
Back to Market Feed

OXYCONTIN ER 40 MG TABLET

oxycodone hydrochloride
$18.7793per EA
High Outlier
DEA Schedule CII

Strength

40 mg/1

Manufacturer

Purdue Pharma LP

NDC

59011044010

Classification

Brand

Dosage Form

TABLET, FILM COATED, EXTENDED RELEASE

Route

ORAL

Last Updated

1/1/2026

Active Ingredients

OXYCODONE HYDROCHLORIDE

Approval Type

New Drug (NDA)

FDA Application

NDA022272

On Market Since

8/8/2010

Pharmacological Classes

Full Opioid Agonists
Opioid Agonist

Price History

1W

0.0%

1M

0.0%

3M

0.0%

6M

+8.5%

1Y

+8.2%

3Y

+25.2%

5Y

+38.3%

All

+164.7%

Generic Alternatives

1 alternative • Same active ingredient

OXYCONTIN ER 40 MG TABLET
Brand
59011044020•Purdue Pharma LP
$18.7793

Related Drugs

Same classification

HYCODAN 5 MG-1.5 MG/5 ML SOLN
Brand
64950034247•Genus Lifesciences Inc.
$0.0505
per ML
DILAUDID 5 MG/5 ML ORAL LIQUID
Brand
42858041616•Rhodes Pharmaceuticals L.P.
$0.8521
per ML
HYCODAN 5 MG-1.5 MG TABLET
Brand
64950020503•Genus Lifesciences Inc.
$1.0146
per EA
HYCODAN 5 MG-1.5 MG TABLET
Brand
64950020510•Genus Lifesciences Inc.
$1.0146
per EA
DILAUDID 4 MG TABLET
Brand
42858023401•Rhodes Pharmaceuticals L.P.
$3.9559
per EA
DILAUDID 4 MG TABLET
Brand
42858023450•Rhodes Pharmaceuticals L.P.
$3.9559
per EA
DEMEROL 50 MG/ML SYRINGE
Brand
00409117830•Hospira Inc.
$4.4738
per ML
MS CONTIN ER 15 MG TABLET
Brand
42858051501•Rhodes Pharmaceuticals L.P.
$4.6807
per EA
SUBOXONE 2 MG-0.5 MG SL FILM
Brand
12496120203•Indivior Inc.
$4.7853
per EA
ZUBSOLV 0.7-0.18 MG TABLET SL
Brand
54123090730•Orexo US, Inc.
$5.2599
per EA

Data Source

Pricing data sourced from the National Average Drug Acquisition Cost (NADAC) survey, published by the Centers for Medicare & Medicaid Services (CMS). Updated weekly.

Disclaimer

This site is for informational purposes only and does not constitute medical, pharmaceutical, or financial advice. NADAC prices are survey-based estimates and may not reflect actual acquisition costs at any specific pharmacy.

Navigate

HomeAboutManufacturersDrug MarketsTherapeutic ClassesTrendsArticlesPricingContact

© 2026 NADAC Intelligence. All rights reserved. Not affiliated with CMS or any government agency.

Terms of ServicePrivacy Policy